vs
Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $183.6M, roughly 1.3× ACV Auctions Inc.). On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 15.1%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-14.7M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 12.3%).
ACV Auctions Inc.ACVAEarnings & Financial Report
ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ACVA vs ANIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.6M | $247.1M |
| Net Profit | — | $27.5M |
| Gross Margin | — | — |
| Operating Margin | -9.7% | 14.1% |
| Net Margin | — | 11.1% |
| Revenue YoY | 15.1% | 29.6% |
| Net Profit YoY | — | 367.5% |
| EPS (diluted) | $-0.12 | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.6M | $247.1M | ||
| Q3 25 | $199.6M | $227.8M | ||
| Q2 25 | $193.7M | $211.4M | ||
| Q1 25 | $182.7M | $197.1M | ||
| Q4 24 | $159.5M | $190.6M | ||
| Q3 24 | $171.3M | $148.3M | ||
| Q2 24 | $160.6M | $138.0M | ||
| Q1 24 | $145.7M | $137.4M |
| Q4 25 | — | $27.5M | ||
| Q3 25 | $-24.5M | $26.6M | ||
| Q2 25 | $-7.3M | $8.5M | ||
| Q1 25 | $-14.8M | $15.7M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | $-16.0M | $-24.2M | ||
| Q2 24 | $-17.1M | $-2.3M | ||
| Q1 24 | $-20.5M | $18.2M |
| Q4 25 | -9.7% | 14.1% | ||
| Q3 25 | -11.9% | 15.9% | ||
| Q2 25 | -3.7% | 6.6% | ||
| Q1 25 | -7.9% | 13.3% | ||
| Q4 24 | -16.2% | -2.3% | ||
| Q3 24 | -10.0% | -13.8% | ||
| Q2 24 | -11.6% | 3.7% | ||
| Q1 24 | -15.5% | 14.8% |
| Q4 25 | — | 11.1% | ||
| Q3 25 | -12.3% | 11.7% | ||
| Q2 25 | -3.8% | 4.0% | ||
| Q1 25 | -8.1% | 8.0% | ||
| Q4 24 | — | -5.4% | ||
| Q3 24 | -9.4% | -16.3% | ||
| Q2 24 | -10.6% | -1.7% | ||
| Q1 24 | -14.1% | 13.2% |
| Q4 25 | $-0.12 | $1.14 | ||
| Q3 25 | $-0.14 | $1.13 | ||
| Q2 25 | $-0.04 | $0.36 | ||
| Q1 25 | $-0.09 | $0.69 | ||
| Q4 24 | $-0.15 | $-0.45 | ||
| Q3 24 | $-0.10 | $-1.27 | ||
| Q2 24 | $-0.10 | $-0.14 | ||
| Q1 24 | $-0.13 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $271.5M | $285.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $429.7M | $540.7M |
| Total Assets | $1.1B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $271.5M | $285.6M | ||
| Q3 25 | $265.3M | $262.6M | ||
| Q2 25 | $258.4M | $217.8M | ||
| Q1 25 | $291.9M | $149.8M | ||
| Q4 24 | $224.1M | $144.9M | ||
| Q3 24 | $252.5M | $145.0M | ||
| Q2 24 | $215.0M | $240.1M | ||
| Q1 24 | $209.8M | $228.6M |
| Q4 25 | $429.7M | $540.7M | ||
| Q3 25 | $434.4M | $505.8M | ||
| Q2 25 | $448.8M | $436.8M | ||
| Q1 25 | $439.6M | $418.6M | ||
| Q4 24 | $440.0M | $403.7M | ||
| Q3 24 | $456.2M | $405.9M | ||
| Q2 24 | $457.6M | $455.8M | ||
| Q1 24 | $458.3M | $452.0M |
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $984.1M | $1.3B | ||
| Q3 24 | $1.0B | $1.3B | ||
| Q2 24 | $1.0B | $920.8M | ||
| Q1 24 | $1.0B | $914.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.4M | $30.4M |
| Free Cash FlowOCF − Capex | $-14.7M | $29.1M |
| FCF MarginFCF / Revenue | -8.0% | 11.8% |
| Capex IntensityCapex / Revenue | 1.2% | 0.5% |
| Cash ConversionOCF / Net Profit | — | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | $69.1M | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.4M | $30.4M | ||
| Q3 25 | $10.3M | $44.1M | ||
| Q2 25 | $13.7M | $75.8M | ||
| Q1 25 | $66.6M | $35.0M | ||
| Q4 24 | $-3.2M | $15.9M | ||
| Q3 24 | $21.1M | $12.5M | ||
| Q2 24 | $4.5M | $17.4M | ||
| Q1 24 | $43.0M | $18.3M |
| Q4 25 | $-14.7M | $29.1M | ||
| Q3 25 | $7.7M | $38.0M | ||
| Q2 25 | $10.9M | $71.8M | ||
| Q1 25 | $65.3M | $32.5M | ||
| Q4 24 | $-3.9M | $13.5M | ||
| Q3 24 | $20.2M | $7.7M | ||
| Q2 24 | $2.7M | $13.0M | ||
| Q1 24 | $41.9M | $13.7M |
| Q4 25 | -8.0% | 11.8% | ||
| Q3 25 | 3.8% | 16.7% | ||
| Q2 25 | 5.6% | 34.0% | ||
| Q1 25 | 35.7% | 16.5% | ||
| Q4 24 | -2.5% | 7.1% | ||
| Q3 24 | 11.8% | 5.2% | ||
| Q2 24 | 1.7% | 9.4% | ||
| Q1 24 | 28.8% | 10.0% |
| Q4 25 | 1.2% | 0.5% | ||
| Q3 25 | 1.3% | 2.7% | ||
| Q2 25 | 1.5% | 1.9% | ||
| Q1 25 | 0.7% | 1.3% | ||
| Q4 24 | 0.4% | 1.3% | ||
| Q3 24 | 0.6% | 3.2% | ||
| Q2 24 | 1.1% | 3.2% | ||
| Q1 24 | 0.7% | 3.3% |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 8.87× | ||
| Q1 25 | — | 2.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACVA
| Auction Marketplace Revenue | $77.6M | 42% |
| Other Marketplace Revenue | $72.4M | 39% |
| Customer Assurance | $24.1M | 13% |
| Data Services Revenue | $9.4M | 5% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
